Results 31 to 40 of about 11,407 (242)

Measuring the Impact of the Substitution of Innovator Biologics With Biosimilars on Uptake and Costs Among Ontario Public Drug Benefit Recipients. [PDF]

Clin Pharmacol Ther
In Ontario, biologics have historically represented a small proportion of public drug claims but a large proportion of spending. Biosimilars, lower cost alternatives to biologics, offer a potential solution to the rising spending on biologics. From March 2023 to January 2024, the Ontario Ministry of Health required public drug program beneficiaries on ...
Iacono A, Ho MKH, Yang J, Campbell T, Wynne W, Shearer D, Andersen L, Majer E, Ledlie S, Tadrous M, Gomes T.   +10 more
europepmc   +2 more sources

Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria

Pharmaceuticals, 2021
The aim of this study is to evaluate the effect of the introduction of biosimilars in Bulgaria on the prices and utilization of biologic disease modifying antirheumatic drugs (bDMARD).
Konstantin Tachkov, Zornitsa Mitkova, Vladimira Boyadzieva, Guenka Petrova   +3 more
doaj   +1 more source

Switching Among Biosimilars: A Review of Clinical Evidence

Frontiers in Pharmacology, 2022
Biological medicines have improved patients’ outcomes, but their high costs may limit access. Biosimilars, alternatives that have demonstrated high similarity in terms of quality, safety, and efficacy to an already licensed originator biological product,
Eleonora Allocati, Brian Godman, Brian Godman, Brian Godman, Marco Gobbi, Silvio Garattini, Rita Banzi   +6 more
doaj   +1 more source

Biosimilar: what it is not [PDF]

British Journal of Clinical Pharmacology, 2015
A biosimilar is a high quality biological medicine shown to be in essence the same as an original product. The European Medicines Agency (EMA) paved the way in the regulatory arena by creating a safeguarding framework for the development of biosimilars.
openaire   +2 more sources

Tendering and biosimilars: what role for value-added services?

Journal of Market Access & Health Policy, 2020
Background: Access to biologic medicines (including biosimilars) across Europe is largely governed by a process of tendering conducted by health authorities. Over-reliance on treatment costs in awarding tenders has the potential to hinder competition and
Steven Simoens, Raymond Cheung
doaj   +1 more source

Biosimilars – terms of use [PDF]

Current Medical Research and Opinion, 2015
The impending expiry of the patent on a number of leading biologic drugs has led to a surge in the development of 'biosimilar' or 'follow-on' products. However, in contrast to generic small-molecule medicines, biosimilars are not identical to their reference products.
Declerck, Paul, Mellstedt, Håkan, Danese, Silvio   +2 more
openaire   +4 more sources

Biosimilars in rheumatology

Pharmacological Research, 2019
Biotechnologicals are an invaluable resource in the treatment of patients with inflammatory rheumatic diseases (IRD) non-responsive or intolerant to conventional therapies. However, they are the main driver for increase in direct costs and represent a significant economic burden to healthcare systems worldwide.
Araújo, Filipe C., Goncalves, Joao, Fonseca, João Eurico   +2 more
openaire   +3 more sources

Biosimilars helfen sparen [PDF]

, 2023
Sie sind gleichwertig und kostengünstiger. Dennoch werden Biosimilars – die Nachahmerprodukte von Biologika – in der Schweiz bisher selten verordnet. Was sind die Gründe dafür?
Ccile Grobet, Renato Mattli, Mattli, Renato, Wieser, Simon, Grobet, Cécile, Simon Wieser   +5 more
core   +1 more source

Biosimilars for the treatment of patients with psoriasis: A consensus statement from the Biosimilar Working Group of the International Psoriasis CouncilCapsule Summary

JAAD International, 2020
Background: As biosimilars have become available in various parts of the world, the International Psoriasis Council has reviewed aspects of their use.
Arnon D. Cohen, MD, MPH, PhD, Ronald Vender, MD, FRCPC, Luigi Naldi, MD, Robert E. Kalb, MD, Tiago Torres, MD, PhD, Murlidhar Rajagopalan, MD, Joelle van der Walt, PhD, Lluís Puig, MD (Hon), PhD, Helen S. Young, MB ChB, PhD, FRCP   +8 more
doaj   +1 more source

Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week‐24 Results of a Phase 3, Randomized, Placebo‐Controlled Study

Arthritis &Rheumatology, EarlyView.
Objective To evaluate the efficacy and safety of guselkumab, an interleukin‐23p19 subunit inhibitor, in participants with active psoriatic arthritis (PsA) and inadequate response (inadequate efficacy and/or intolerance) to one prior tumor necrosis factor (TNF) inhibitor.
Alexis Ogdie, Joseph F. Merola, Philip J. Mease, Christopher T. Ritchlin, Jose U. Scher, Kimberly Parnell Lafferty, Daphne Chan, Soumya D. Chakravarty, Wayne Langholff, Yanli Wang, Jie Shao, Yevgeniy Krol, Alice B. Gottlieb   +12 more
wiley   +1 more source